Endo, a global pharmaceutical company, has reported, its financial results for the second quarter ended 30 June 2020 on Wednesday.

The company reported total revenues at USD688m in the second quarter of 2020, down 2% compared to the year-ago period.

The firm posted income from continuing operations in the second-quarter 2020 at USD18m compared to reported loss from continuing operations of USD98m in the same period in 2019. Diluted net income per share from continuing operations was USD0.08, compared with a loss of USD0.43 per share for the year ago period.

Blaise Coleman, president and chief executive officer at Endo, said, 'I'm proud of what our team delivered in the second quarter. Our Branded Pharmaceuticals segment performed better than previously guided as COVID-19 related restrictions and physician office closures began easing throughout the quarter. Additionally, our Sterile Injectables segment delivered strong revenue growth versus prior year as customers built significant inventory levels of products used to treat certain COVID-19 patients. I want to thank our team members for their tireless work and dedication to meeting our customers' needs in a challenging environment.'